Xeris Biopharma Holdings Inc

NASDAQ:XERS  
1.56
+0.01 (+0.64%)
6:59:23 PM EDT: $1.57 +0.01 (+0.64%)
Positive Earnings Pre-Announcement

Xeris Biopharma Reports Third Quarter 2022 Financial Results And Recent Events

Published: 11/09/2022 12:30 GMT
Xeris Biopharma Holdings Inc (XERS) - Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events.
Co Ended Q3 With $93.4m in Cash, Cash Equivalents and Short-term Investments.
Raises 2022 Year-end Cash Balance Guidance From $90 Million -$110 Million to $110 Million-$120m Million.
Remains on Track to Achieve $50m in Synergies by Year-end 2022 and Cash Flow Breakeven by Year-end 2023.
Qtrly Loss per Share $0.16.
Q3 Earnings per Share View $-0.17 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $30.94 Million
Adjusted EPS is expected to be -$0.15

Next Quarter Revenue Guidance is expected to be $31.09 Million
Next Quarter EPS Guidance is expected to be -$0.15

More details on our Analysts Page.